|Other Names||Exostosin-2, Glucuronosyl-N-acetylglucosaminyl-proteoglycan/N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase, Multiple exostoses protein 2, Putative tumor suppressor protein EXT2, EXT2|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Glycosyltransferase required for the biosynthesis of heparan-sulfate. The EXT1/EXT2 complex possesses substantially higher glycosyltransferase activity than EXT1 or EXT2 alone. Appears to be a tumor suppressor. Required for the exosomal release of SDCBP, CD63 and syndecan (PubMed:22660413).|
|Cellular Location||Endoplasmic reticulum membrane; Single-pass type II membrane protein. Golgi apparatus membrane; Single-pass type II membrane protein. Note=The EXT1/EXT2 complex is localized in the Golgi apparatus|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes one of two glycosyltransferases involvedin the chain elongation step of heparan sulfate biosynthesis.Mutations in this gene cause the type II form of multipleexostoses. Alternatively spliced transcript variants encodingdifferent isoforms have been noted for this gene. [provided byRefSeq].
Yang, L., et al. J. Orthop. Res. 28(11):1522-1530(2010)Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Fontaine-Bisson, B., et al. Diabetologia 53(10):2155-2162(2010)Chidambaram, M., et al. Metab. Clin. Exp. (2010) In press :Philippe, C., et al. Am. J. Hum. Genet. 61(3):520-528(1997)
If you have any additional inquiries please email technical services at email@example.com.